Arbutus Biopharma (ABUS) Capital Expenditures (QoQ) (2013 - 2024)
Arbutus Biopharma (ABUS) Capital Expenditures (QoQ) (2013 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Arbutus Biopharma | 922.95 Mn | 830.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -98.95% |
| Sep 30, 2023 | -96.27% |
| Jun 30, 2023 | 634.19% |
| Mar 31, 2023 | -12.69% |
| Dec 31, 2022 | 47.25% |
| Sep 30, 2022 | -57.08% |
| Jun 30, 2022 | 182.67% |
| Mar 31, 2022 | 29.31% |
| Dec 31, 2021 | 190.00% |
| Sep 30, 2021 | -96.84% |
| Jun 30, 2021 | 538.38% |
| Mar 31, 2021 | -34.87% |
| Dec 31, 2020 | 1,281.82% |
| Sep 30, 2020 | -83.33% |
| Dec 31, 2019 | -75.29% |
| Sep 30, 2019 | 6.25% |
| Jun 30, 2019 | 674.19% |
| Mar 31, 2019 | -86.34% |
| Dec 31, 2018 | -4.22% |
| Sep 30, 2018 | -44.24% |